Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early defects in B cell development.

Mary Ellen Conley1

  • 1Department of Pediatrics, University of Tennessee College of Medicine, Memphis, 38105, USA. maryellen.conley@stjude.org

Current Opinion in Allergy and Clinical Immunology
|January 31, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An essential role for the Zn<sup>2+</sup> transporter ZIP7 in B cell development.

Nature immunology·2019
Same author

Hyper IgM Syndrome: a Report from the USIDNET Registry.

Journal of clinical immunology·2016
Same author

Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015.

Journal of clinical immunology·2015
Same author

CD19 controls Toll-like receptor 9 responses in human B cells.

The Journal of allergy and clinical immunology·2015
Same author

The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies.

Journal of clinical immunology·2015
Same author

Enteroviral Infection in a Patient with BLNK Adaptor Protein Deficiency.

Journal of clinical immunology·2015
Same journal

Biosimilars in allergology: an outline in pediatric patients.

Current opinion in allergy and clinical immunology·2026
Same journal

The immunogenetic landscape of systemic lupus erythematosus.

Current opinion in allergy and clinical immunology·2026
Same journal

Circadian control of innate immunity: molecular mechanisms and implications for allergic disorders.

Current opinion in allergy and clinical immunology·2026
Same journal

Probiotics in allergic disease: from adjunct supplement to immune-modifying strategy (2026 update).

Current opinion in allergy and clinical immunology·2026
Same journal

Updates on drug-induced anaphylaxis in children.

Current opinion in allergy and clinical immunology·2026
Same journal

Beta-lactam de-labelling as a core antimicrobial stewardship strategy in the era of the antimicrobial resistance pandemic: a narrative review.

Current opinion in allergy and clinical immunology·2026
See all related articles

Early diagnosis and prompt gammaglobulin therapy are crucial for managing X-linked and autosomal recessive agammaglobulinemia. Timely intervention improves outcomes and reduces complications in patients with these primary immunodeficiencies.

Area of Science:

  • Immunology
  • Genetics
  • Pediatrics

Background:

  • Primary immunodeficiencies like X-linked agammaglobulinemia (XLA) and autosomal recessive agammaglobulinemia (ARA) significantly impact B cell development.
  • Delayed diagnosis and treatment lead to severe infections and chronic complications.

Purpose of the Study:

  • To review current clinical guidelines for managing patients with suspected immunodeficiency.
  • To highlight areas for improvement in the diagnosis and management of B cell defects.

Main Methods:

  • Review of recent clinical studies and patient data.
  • Analysis of diagnostic delays and treatment initiation in XLA and ARA.
  • Correlation of clinical presentation with disease outcomes.

Related Experiment Videos

Main Results:

  • Males at high risk for XLA are often diagnosed late, after hospitalization for infection.
  • Early diagnosis (by 2-3 months) and prompt gammaglobulin therapy are recommended for known XLA.
  • Autosomal recessive agammaglobulinemia presents earlier and may have more severe complications than XLA.

Conclusions:

  • Significant improvements are needed in the early diagnosis and timely management of agammaglobulinemia.
  • Increased awareness of clinical clues and prompt evaluation can facilitate earlier diagnosis.